Stephan R Seibert1, David P Schladt2, Baolin Wu3, Weihua Guan3, Casey Dorr4, Rory P Remmel5, Arthur J Matas6, Roslyn B Mannon7, Ajay K Israni8, William S Oetting9, Pamala A Jacobson1. 1. Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota. 2. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, Minnesota. 3. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 4. Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, Minnesota. 5. Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota. 6. Department of Surgery, University of Minnesota, Minneapolis, Minnesota. 7. Department of Nephrology, University of Alabama, Birmingham, Alabama. 8. Division of Nephrology, Hennepin County Medical Center, Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota. 9. Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Suboptimal immunosuppression after kidney transplantation contributes to toxicity and loss of efficacy. Little is known regarding the impact of intra-patient variability of tacrolimus (TAC) doses and troughs in the early post-transplant period or the influence of genetic variants on variability. METHODS: Coefficients of variation (CV) of TAC troughs and doses of 1226 European American (EA) and 246 African American (AA) adult recipients enrolled in DeKAF Genomics were compared for association with acute rejection and graft failure. Additionally, the influence of recipients' number of CYP3A5 loss-of-function alleles was assessed. RESULTS: Acute rejection was associated with greater CV of dose in AA (P < 0.001) and EA recipients (P = 0.012). Graft failure was associated with a greater CV of dose (P = 0.022) and trough (P < 0.001) in AA, and higher CV of trough (P = 0.024) in EA recipients. In EA, CYP3A5 loss-of-function alleles were associated with decreased CV of trough (P = 0.0042) and increased CV of dose (P < 0.0001). CONCLUSION: CYP3A5 loss-of-function alleles influence intra-patient TAC trough and dose variability. High variability of TAC dose increases risk of acute rejection. High variability of TAC trough increases risk of graft failure. Early clinical recognition of TAC dose and trough variability may improve patient management and outcomes.
BACKGROUND: Suboptimal immunosuppression after kidney transplantation contributes to toxicity and loss of efficacy. Little is known regarding the impact of intra-patient variability of tacrolimus (TAC) doses and troughs in the early post-transplant period or the influence of genetic variants on variability. METHODS: Coefficients of variation (CV) of TAC troughs and doses of 1226 European American (EA) and 246 African American (AA) adult recipients enrolled in DeKAF Genomics were compared for association with acute rejection and graft failure. Additionally, the influence of recipients' number of CYP3A5 loss-of-function alleles was assessed. RESULTS: Acute rejection was associated with greater CV of dose in AA (P < 0.001) and EA recipients (P = 0.012). Graft failure was associated with a greater CV of dose (P = 0.022) and trough (P < 0.001) in AA, and higher CV of trough (P = 0.024) in EA recipients. In EA, CYP3A5 loss-of-function alleles were associated with decreased CV of trough (P = 0.0042) and increased CV of dose (P < 0.0001). CONCLUSION:CYP3A5 loss-of-function alleles influence intra-patientTAC trough and dose variability. High variability of TAC dose increases risk of acute rejection. High variability of TAC trough increases risk of graft failure. Early clinical recognition of TAC dose and trough variability may improve patient management and outcomes.
Authors: Barry D Kahan; Maria Welsh; Diana L Urbauer; Melinda B Mosheim; Kathleen M Beusterien; Martha R Wood; Linda P Schoenberg; Joseph Dicesare; Stephen M Katz; Charles T VAN Buren Journal: J Am Soc Nephrol Date: 2000-06 Impact factor: 10.121
Authors: Sarah Schmid; Rhonda Bryce; Bruce Reeder; Masud Rana; Punam Pahwa; Ahmed Shoker; Michael A J Moser Journal: Ann Transplant Date: 2014-08-15 Impact factor: 1.530
Authors: Nilufar Pashaee; Rachida Bouamar; Dennis A Hesselink; Joke I Roodnat; Ron H N van Schaik; Willem Weimar; Teun van Gelder Journal: Ther Drug Monit Date: 2011-06 Impact factor: 3.681
Authors: Emilio Rodrigo; David San Segundo; Gema Fernández-Fresnedo; Marcos López-Hoyos; Adalberto Benito; Juan Carlos Ruiz; Maria-Angeles de Cos; Manuel Arias Journal: Transplantation Date: 2016-11 Impact factor: 4.939
Authors: Yun R Li; Jessica van Setten; Shefali S Verma; Yontao Lu; Michael V Holmes; Hui Gao; Monkol Lek; Nikhil Nair; Hareesh Chandrupatla; Baoli Chang; Konrad J Karczewski; Chanel Wong; Maede Mohebnasab; Eyas Mukhtar; Randy Phillips; Vinicius Tragante; Cuiping Hou; Laura Steel; Takesha Lee; James Garifallou; Toumy Guettouche; Hongzhi Cao; Weihua Guan; Aubree Himes; Jacob van Houten; Andrew Pasquier; Reina Yu; Elena Carrigan; Michael B Miller; David Schladt; Abdullah Akdere; Ana Gonzalez; Kelsey M Llyod; Daniel McGinn; Abhinav Gangasani; Zach Michaud; Abigail Colasacco; James Snyder; Kelly Thomas; Tiancheng Wang; Baolin Wu; Alhusain J Alzahrani; Amein K Al-Ali; Fahad A Al-Muhanna; Abdullah M Al-Rubaish; Samir Al-Mueilo; Dimitri S Monos; Barbara Murphy; Kim M Olthoff; Cisca Wijmenga; Teresa Webster; Malek Kamoun; Suganthi Balasubramanian; Matthew B Lanktree; William S Oetting; Pablo Garcia-Pavia; Daniel G MacArthur; Paul I W de Bakker; Hakon Hakonarson; Kelly A Birdwell; Pamala A Jacobson; Marylyn D Ritchie; Folkert W Asselbergs; Ajay K Israni; Abraham Shaked; Brendan J Keating Journal: Genome Med Date: 2015-10-01 Impact factor: 11.117
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Dana R Pierce; Patricia West-Thielke; Zahraa Hajjiri; Sujata Gaitonde; Ivo Tzvetanov; Enrico Benedetti; Alicia B Lichvar Journal: Transplant Direct Date: 2021-05-18
Authors: Amy L Pasternak; Vincent D Marshall; Christina L Gersch; James M Rae; Michael Englesbe; Jeong M Park Journal: Pharmgenomics Pers Med Date: 2021-03-12
Authors: Kim L W Bunthof; Linda Al-Hassany; Gizal Nakshbandi; Dennis A Hesselink; Ron H N van Schaik; Marc A G J Ten Dam; Marije C Baas; Luuk B Hilbrands; Teun van Gelder Journal: Clin Transl Sci Date: 2021-12-15 Impact factor: 4.438
Authors: Joy Obayemi; Brendan Keating; Lauren Callans; Krista L Lentine; Mark A Schnitzler; Yasar Caliskan; Huiling Xiao; Vikas R Dharnidharka; Roslyn B Mannon; David A Axelrod Journal: Transplant Direct Date: 2022-09-15
Authors: Chris Wiebe; David N Rush; Ian W Gibson; Denise Pochinco; Patricia E Birk; Aviva Goldberg; Tom Blydt-Hansen; Martin Karpinski; Jamie Shaw; Julie Ho; Peter W Nickerson Journal: Am J Transplant Date: 2020-04-09 Impact factor: 8.086